Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

EMERYVILLE, Calif., Feb. 12, 2024 /PRNewswire/ — Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the closing of its upsized initial…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertisement — Advertise with Biotech Networks